Parallel Buprenorphine phMRI Responses in Conscious Rodents and Healthy Human Subjects

Baker, 2012, Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection, J Pharmacol Exp Ther, 341, 263, 10.1124/jpet.111.188797

Becerra, 2011, CNS activation maps in awake rats exposed to thermal stimuli to the dorsum of the hindpaw, Neuroimage, 54, 1355, 10.1016/j.neuroimage.2010.08.056

Becerra, 2006, Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers, Anesth Analg, 103, 208, 10.1213/01.ane.0000221457.71536.e0

Becerra, 2011, Robust reproducible resting state networks in the awake rodent brain, PLoS ONE, 6, e25701, 10.1371/journal.pone.0025701

Bifone, 2012, Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics, Expert Opin Drug Discov, 7, 1071, 10.1517/17460441.2012.724057

Borras, 2004, fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers, J Neurophysiol, 91, 2723, 10.1152/jn.00249.2003

Borsook, 2012, Neurological diseases and pain, Brain, 135, 320, 10.1093/brain/awr271

Breiter, 1997, Acute effects of cocaine on human brain activity and emotion, Neuron, 19, 591, 10.1016/S0896-6273(00)80374-8

Brown, 2011, Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active, Anesthesiology, 115, 1251, 10.1097/ALN.0b013e318238fea0

Chen, 2011, Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI after a single dose of oral citalopram, Clin Pharmacol Ther, 89, 251, 10.1038/clpt.2010.296

Chen, 2005, Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI, Synapse, 55, 80, 10.1002/syn.20091

Chin, 2011, Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals, J Pharmacol Exp Ther, 336, 709, 10.1124/jpet.110.173880

Christoph, 2005, Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain, Eur J Pharmacol, 507, 87, 10.1016/j.ejphar.2004.11.052

Cole, 2012, Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents, Clin Pharmacol Ther, 91, 315, 10.1038/clpt.2011.286

Day, 2009, Translational medicine—a paradigm shift in modern drug discovery and development: the role of biomarkers, Adv Exp Med Biol, 655, 1, 10.1007/978-1-4419-1132-2_1

De Simoni, 2013, Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers, Neuroimage, 10.1016/j.neuroimage.2012.09.037

Elman, 2011, The missing p in psychiatric training: why it is important to teach pain to psychiatrists, Arch Gen Psychiatry, 68, 12, 10.1001/archgenpsychiatry.2010.174

Escher, 2007, Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study, Clin Ther, 29, 1620, 10.1016/j.clinthera.2007.08.007

Ferris, 2006, Functional magnetic resonance imaging in conscious animals: a new tool in behavioural neuroscience research, J Neuroendocrinol, 18, 307, 10.1111/j.1365-2826.2006.01424.x

Feuerstein, 2009, Translational medicine for stroke drug discovery: the pharmaceutical industry perspective, Stroke, 40, S121

Fox, 2009, Translational neuroimaging of the CNS: novel pathways to drug development, Mol Interv, 9, 302, 10.1124/mi.9.6.6

Goodman, 1985, Visualization of mu1 opiate receptors in rat brain by using a computerized autoradiographic subtraction technique, Proc Natl Acad Sci USA, 82, 6667, 10.1073/pnas.82.19.6667

Gopal, 2002, Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine, Eur J Pharm Sci, 15, 287, 10.1016/S0928-0987(02)00009-X

Gozzi, 2010, Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit, Psychopharmacology (Berl), 209, 37, 10.1007/s00213-009-1772-4

Gozzi, 2008, Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine, Neuropsychopharmacology, 33, 1690, 10.1038/sj.npp.1301547

Gozzi, 2006, Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naïve rat, Neuropsychopharmacology, 31, 1690, 10.1038/sj.npp.1300955

Guetti, 2011, Transdermal buprenorphine for central neuropathic pain: clinical reports, Pain Pract, 11, 446, 10.1111/j.1533-2500.2010.00434.x

Hans, 2007, Buprenorphine—a review of its role in neuropathic pain, J Opioid Manag, 3, 195, 10.5055/jom.2007.0005

Hawkinson, 2000, Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors, Eur J Pharmacol, 389, 107, 10.1016/S0014-2999(99)00904-8

Hodkinson, 2012, Differential effects of anaesthesia on the phMRI response to acute ketamine challenge, Br J Med Res, 2, 373, 10.9734/BJMMR/2012/1412

Hreiche, 2006, Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression, Toxicol Appl Pharmacol, 217, 352, 10.1016/j.taap.2006.09.011

Huang, 2001, Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist, J Pharmacol Exp Ther, 297, 688

Ide, 2004, Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice, Neuropsychopharmacology, 29, 1656, 10.1038/sj.npp.1300463

Jenkins, 2012, Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain, Neuroimage, 62, 1072, 10.1016/j.neuroimage.2012.03.075

Jenkins, 2004, Mapping dopamine function in primates using pharmacologic magnetic resonance imaging, J Neurosci, 24, 9553, 10.1523/JNEUROSCI.1558-04.2004

Johnson, 2005, Buprenorphine: considerations for pain management, J Pain Symptom Manage, 29, 297, 10.1016/j.jpainsymman.2004.07.005

Jonckers, 2011, Functional connectivity fMRI of the rodent brain: comparison of functional connectivity networks in rat and mouse, PLoS ONE, 6, e18876, 10.1371/journal.pone.0018876

Keller, 2006, Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder, Biol Psychiatry, 59, 216, 10.1016/j.biopsych.2005.07.013

Kouya, 2002, Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury, Eur J Pharmacol, 450, 49, 10.1016/S0014-2999(02)02052-6

Large, 2011, The efficacy of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the rat: potential for novel treatments for schizophrenia, J Pharmacol Exp Ther, 338, 100, 10.1124/jpet.110.178475

Leppä, 2006, Acute opioid effects on human brain as revealed by functional magnetic resonance imaging, Neuroimage, 31, 661, 10.1016/j.neuroimage.2005.12.019

Leslie, 2000, Pharmacological magnetic resonance imaging: a new application for functional MRI, Trends Pharmacol Sci, 21, 314, 10.1016/S0165-6147(00)01507-8

Liang, 2011, Uncovering intrinsic connectional architecture of functional networks in awake rat brain, J Neurosci, 31, 3776, 10.1523/JNEUROSCI.4557-10.2011

Liang, 2012, Intrinsic organization of the anesthetized brain, J Neurosci, 32, 10183, 10.1523/JNEUROSCI.1020-12.2012

Littlewood, 2006, Mapping the central effects of ketamine in the rat using pharmacological MRI, Psychopharmacology (Berl), 186, 64, 10.1007/s00213-006-0344-0

Liu, 2007, Remifentanil administration reveals biphasic phMRI temporal responses in rat consistent with dynamic receptor regulation, Neuroimage, 34, 1042, 10.1016/j.neuroimage.2006.10.028

Lu, 2012, Rat brains also have a default mode network, Proc Natl Acad Sci USA, 109, 3979, 10.1073/pnas.1200506109

Luan, 2008, Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys, Cell Transplant, 17, 417, 10.3727/096368908784423319

Lutfy, 2003, Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors, J Neurosci, 23, 10331, 10.1523/JNEUROSCI.23-32-10331.2003

Majeed, 2011, Spatiotemporal dynamics of low frequency BOLD fluctuations in rats and humans, Neuroimage, 54, 1140, 10.1016/j.neuroimage.2010.08.030

Mansour, 1995, Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications, Trends Neurosci, 18, 22, 10.1016/0166-2236(95)93946-U

Mansour, 1987, Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain, J Neurosci, 7, 2445

Marek, 1996, [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease, Neurology, 46, 231, 10.1212/WNL.46.1.231

McKie, 2011, Mirtazapine antagonises the subjective, hormonal and neuronal effects of m-chlorophenylpiperazine (mCPP) infusion: a pharmacological-challenge fMRI (phMRI) study, Neuroimage, 58, 497, 10.1016/j.neuroimage.2011.06.049

Nordberg, 2004, PET imaging of amyloid in Alzheimer’s disease, Lancet Neurol, 3, 519, 10.1016/S1474-4422(04)00853-1

Ohtani, 1994, Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats, Drug Metab Dispos, 22, 2

Pendse, 2009, Enhanced false discovery rate using Gaussian mixture models for thresholding fMRI statistical maps, Neuroimage, 47, 231, 10.1016/j.neuroimage.2009.02.035

Pendse, 2010, Robust, unbiased general linear model estimation of phMRI signal amplitude in the presence of variation in the temporal response profile, J Magn Reson Imaging, 31, 1445, 10.1002/jmri.22180

Peng, 2012, Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR, Drug Alcohol Depend, 124, 223, 10.1016/j.drugalcdep.2012.01.013

Pergolizzi, 2010, Current knowledge of buprenorphine and its unique pharmacological profile, Pain Pract, 10, 428, 10.1111/j.1533-2500.2010.00378.x

Pergolizzi, 2009, The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus, Curr Med Res Opin, 25, 1517, 10.1185/03007990902920731

Raichle, 2001, A default mode of brain function, Proc Natl Acad Sci USA, 98, 676, 10.1073/pnas.98.2.676

Rothman, 1995

Sadée, 1982, Buprenorphine: differential interaction with opiate receptor subtypes in vivo, J Pharmacol Exp Ther, 223, 157

Sawle, 1993, Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status, Brain, 116, 853, 10.1093/brain/116.4.853

Schlaepfer, 1998, Site of opioid action in the human brain: mu and kappa agonists’ subjective and cerebral blood flow effects, Am J Psychiatry, 155, 470, 10.1176/ajp.155.4.470

Schwarz, 2007, In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI, Neuroimage, 34, 1627, 10.1016/j.neuroimage.2006.11.010

Schwarz, 2004, Concurrent pharmacological MRI and in situ microdialysis of cocaine reveal a complex relationship between the central hemodynamic response and local dopamine concentration, Neuroimage, 23, 296, 10.1016/j.neuroimage.2004.05.001

Tracey, 2012, SnapShot: Pain perception, Cell, 148, 1308, 10.1016/j.cell.2012.03.004

Upadhyay, 2012, Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine, Neuroimage, 59, 3762, 10.1016/j.neuroimage.2011.11.034

Upadhyay, 2011, Imaging drugs with and without clinical analgesic efficacy, Neuropsychopharmacology, 36, 2659, 10.1038/npp.2011.156

Vadivelu, 2010, Buprenorphine in postoperative pain management, Anesthesiol Clin, 28, 601, 10.1016/j.anclin.2010.08.015

Vincent, 2007, Intrinsic functional architecture in the anaesthetized monkey brain, Nature, 447, 83, 10.1038/nature05758

Völlm, 2004, Methamphetamine activates reward circuitry in drug naïve human subjects, Neuropsychopharmacology, 29, 1715, 10.1038/sj.npp.1300481

Wan, 2009, Translational medicine lessons from flurizan’s failure in Alzheimer’s disease (AD) trial: Implication for future drug discovery and development for AD, Clin Transl Sci, 2, 242, 10.1111/j.1752-8062.2009.00121.x

Wong, 2009, The role of imaging in proof of concept for CNS drug discovery and development, Neuropsychopharmacology, 34, 187, 10.1038/npp.2008.166

Yassen, 2006, Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers, Anesthesiology, 104, 1232, 10.1097/00000542-200606000-00019

Zhang, 2001, Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys, Neuroimage, 14, 1159, 10.1006/nimg.2001.0902

Zubieta, 2000, Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study, Neuropsychopharmacology, 23, 326, 10.1016/S0893-133X(00)00110-X